Flash Finance
Follow Flash Finance FollowTelegram

Vivimed Labs LimitedVIVIMEDLABCorporate

Pharmaceuticals Latest results: Mar 2026 1 quarters of data
Consolidated Standalone
₹5.42
MCap ₹45 Cr
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹12 Cr
Sales · Mar 2026
₹-140 Cr
Operating Profit · Mar 2026
-1169.0%
OPM % · Mar 2026
₹-147 Cr
Net Profit · Mar 2026
₹-17.74
EPS · Mar 2026

📝 Vivimed Labs Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Vivimed Labs Limited reported revenue of ₹12 crore for the quarter ended March 2026 (Q4 FY26).

The company reported a net loss of ₹147 crore. Earnings per share (EPS) came in at ₹-17.74.

Operating profit stood at ₹-140 crore — an operating margin (OPM) of -1169.0%.

Valuation snapshot

At the current price of ₹5.42, VIVIMEDLAB has a market capitalisation of ₹45 crore.

Within the Pharmaceuticals industry, it is the 25th-largest of the 83 companies we track by market value.

Related 🏭 Pharma sector

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹45 Cr
Current Price ?
₹5.4
P/E ?
N/A
Industry P/E ?
22.50
P/B ?
-0.21
P/S ?
N/A
P/FCF ?
N/A
Enterprise Value ?
₹442 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
N/A
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
N/A
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹12 Cr
PAT — latest qtr ?
₹-147 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
N/A
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹397 Cr
Debt to Equity ?
-1.89
Interest Coverage ?
N/A
Ownership
Promoter holding ?
N/A
Change in promoter holding ?
N/A
FII holding ?
N/A
DII holding ?
N/A
Market
Return 3 months ?
7.5%
Return 6 months ?
-19.0%

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2026 YoY % QoQ %
Sales 12 — —
Operating Profit -140 — —
Other Income 6 — —
Interest 1 — —
Depreciation 12 — —
Profit Before Tax -147 — —
Net Profit -147 — —
EPS -17.74 — —
OPM % -1169.0% — —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 1 periods)

Metric Mar 2026 % Chg
Equity Capital 17 —
Reserves -227 —
Borrowings 397 —
Other Liabilities 567 —
Total Liabilities 753 —
Fixed Assets 386 —
CWIP 18 —
Investments 181 —
Other Assets 170 —
Total Assets 753 —

📦 Working Capital (latest 1 periods)

Metric Mar 2026 % Chg
Inventories 13 —
Trade Receivables 45 —
Trade Payables 53 —

💧 Cash Flow (latest 1 periods)

Metric Mar 2026 % Chg
Cash from Operating Activity 8 —
Cash from Investing Activity -1 —
Cash from Financing Activity -6 —
Net Cash Flow 1 —

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 83 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% ROE% ROCE% D/E Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 61.8 709 189 35.4% 26.7% 19.8% — 0.20 — — 20.9% 10.8%
2 SPARC Sun Pharma ₹185.08 6,006 3.7 1,931 1,636 84.7% 84.7% 113.4% 164.0% 0.00 2512.3% 553.9% 282.1% 67.8%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% — — — 8.6% -6.1% 21.6% 23.0%
4 539997 Kwality Pharmaceuticals ₹2,652.10 3,348 34.0 553 81 24.4% 14.6% — — — 35.7% 71.8% 46.3% 113.5%
5 524632 Shukra Pharmaceuticals ₹80.95 2,403 99.9 75 36 65.0% 48.2% — — — 74.0% 130.1% 336.4% 1359.2%
6 FERMENTA Fermenta Biotech ₹465.00 1,333 20.9 501 64 18.9% 12.7% — — — — — -17.9% -30.6%
7 506414 Fermenta Biotech ₹552.60 1,313 27.2 511 59 17.6% 11.5% — — — 11.9% -6.6% -10.4% -56.7%
8 AHCL Anlon Healthcare ₹24.66 1,311 31.6 280 42 24.5% 14.9% — — — — — — —
9 541096 Bharat Parenterals ₹1,525.00 1,045 — 395 -10 8.4% -2.4% — — — 1.5% 37.5% 110.9% 237.4%
10 540737 Shree Ganesh ₹796.30 844 84.4 92 12 27.6% 13.2% — — — 0.7% -23.0% -23.2% -67.1%
11 AMANTA Amanta Healthcare ₹163.87 636 43.5 291 15 20.4% 5.0% — — — — — 5.4% -5.6%
12 539730 Fredun Pharmaceuticals ₹827.85 611 10.3 747 44 14.7% 5.9% — — — 40.1% 90.0% 90.2% 88.1%
13 500422 Transchem Ltd-$ ₹38.00 474 6.9 — 7 — — — — — -100.0% -17.8% — 245.6%
14 HALEOSLABS Haleos Labs ₹1,525.00 461 21.0 324 15 12.6% 4.7% — — — -3.2% -4.9% -11.6% -58.0%
15 524731 Jenburkt Pharmaceuticals ₹865.75 380 11.6 170 33 23.6% 19.4% — — — 11.8% 6.1% -1.4% -26.4%
16 543616 Trident Lifeline ₹279.85 363 11.0 166 31 26.2% 18.4% — — — — — 117.1% 134.7%
17 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% — — — 142.9% -9.0% 56.0% 77.4%
18 524828 BDH Industries ₹336.80 300 16.6 100 12 15.3% 11.7% — — — 44.3% 16.6% 20.2% 48.8%
19 500009 Ambalal Sarabhai ₹38.73 297 21.9 206 14 7.1% 6.6% — — — 3.1% 261.1% 8.0% -51.6%
20 531739 Gennex Laboratories ₹13.87 255 19.0 183 21 14.4% 11.3% — — — 24.9% 15.5% 16.6% -6.9%
21 524790 Everest Organics ₹159.20 252 29.4 191 5 10.3% 2.8% — — — 23.0% 527.7% -10.0% -21.1%
22 532039 Zenotech Laboratories ₹64.90 234 — 41 -4 8.1% -10.5% — — — 1.3% -119.2% -36.4% -206.3%
23 524506 Coral Laboratories ₹680.20 228 12.7 97 19 19.2% 19.9% — — — -25.3% -32.2% 57.4% 110.5%
24 530163 Kerala Ayurveda ₹310.20 225 — 125 -26 -14.9% -20.8% — — — 9.0% -16.8% -21.3% -477.8%
25 VIVIMEDLAB Vivimed Labs ₹6.45 53 — — — — — — — -1.89 — — — —
❓ Frequently asked questions
What was Vivimed Labs Limited's revenue in Q4 FY26?
Vivimed Labs Limited reported revenue of ₹12 crore for the quarter ended March 2026 (Q4 FY26).
What was Vivimed Labs Limited's net profit in Q4 FY26?
The company reported a net loss of ₹147 crore. Earnings per share (EPS) came in at ₹-17.74.
What is VIVIMEDLAB's market capitalisation and P/E ratio?
At the current price of ₹5.42, VIVIMEDLAB has a market capitalisation of ₹45 crore.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI